Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia
Nobuko Hijiya(Lurie Children's Hospital), Paul S. Gaynon(University of Southern California), Richard Kadota(Roswell Park Comprehensive Cancer Center), Todd M. Cooper(Seattle Children's Hospital), Roland Chu(Children's Hospital of Michigan), Elly Barry, Sima Jeha(St. Jude Children's Research Hospital), Lewis B. Silverman(Columbia University Irving Medical Center), Jo-Anne Paul, Joseph G. Pressey(Cincinnati Children's Hospital Medical Center), Bassem I. Razzouk(Peyton Manning Children’s Hospital at St.Vincent), William L. Carroll(NYU Langone Health), Blythe Thomson(Epizyme (United States)), Michael J. Borowitz(Johns Hopkins University), Michael Rytting(The University of Texas MD Anderson Cancer Center), Michael S. Isakoff(Center for Cancer and Blood Disorders), Violet Shen(Ruhr University Bochum), Peter G. Steinherz(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|1.2k